We Offer Worldwide Shipping
Login Wishlist

Quercetin 3-O-sophoroside-7-O-rhamnoside

$1,344

  • Brand : BIOFRON

  • Catalogue Number : BD-P0762

  • Specification : 95.0%(HPLC)

  • CAS number : 64828-40-6

  • Formula : C33H40O21

  • Molecular Weight : 772.658

  • PUBCHEM ID : 102085574

  • Volume : 25mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BD-P0762

Analysis Method

HPLC,NMR,MS

Specification

95.0%(HPLC)

Storage

2-8°C

Molecular Weight

772.658

Appearance

Powder

Botanical Source

Structure Type

Flavonoids

Category

SMILES

CC1C(C(C(C(O1)OC2=CC(=C3C(=C2)OC(=C(C3=O)OC4C(C(C(C(O4)CO)O)O)OC5C(C(C(C(O5)CO)O)O)O)C6=CC(=C(C=C6)O)O)O)O)O)O

Synonyms

3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one

IUPAC Name

3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-(3,4-dihydroxyphenyl)-5-hydroxy-7-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one

Applications

Density

Solubility

Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.

Flash Point

Boiling Point

Melting Point

InChl

InChI=1S/C33H40O21/c1-9-19(39)23(43)26(46)31(48-9)49-11-5-14(38)18-15(6-11)50-28(10-2-3-12(36)13(37)4-10)29(22(18)42)53-33-30(25(45)21(41)17(8-35)52-33)54-32-27(47)24(44)20(40)16(7-34)51-32/h2-6,9,16-17,19-21,23-27,30-41,43-47H,7-8H2,1H3/t9-,16+,17+,19-,20+,21+,23+,24-,25-,26+,27+,30+,31-,32-,33-/m0/s1

InChl Key

CAXLTZYEJPQCKD-SBQRELSASA-N

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:64828-40-6) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

7458308

Abstract

Groups of 16 rabbits per strain were injected with broth culture dilutions of three Kanagawa-positive Vibrio parahaemolyticus strains. The effective dose required to produce ileal loop dilatation in 50% of rabbits for pure cultures of strains 10136-76 and 553-72 from patients stools and NY 477 from incriminated food was 1.1 x 10(6), 2.6 x 10(5), and 7.7 x 10(6) organisms, respectively. When each of these cultures was admixed with greater than or equal to 10(9) Vibrio alginolyticus cells, the 50% effective dose was 1.2 x 10(6), 1.1 x 10(7), and 1.3 x 10(8) cells, respectively. Although concomitant injection of large numbers of competitive nonvirulent cells did not affect the 50% effective dose for strain 10136-76, that for the remaining two was increased 20- to 40-fold. The initiation of ileal loop response as estimated from sigmoidal plots of proportion of positive loops versus cell concentrations was given by as few as 10(2) cells of strain 553-72. Strains NY 477 and 10136-76 required approximately 10(5) cells. Half of the maximal response from these plots corresponded well with the 50% effective dose for the strains. These results suggest that pathogenicity of Kanagawa-positive V. parahaemolyticus strains may involve the participation of some virulence mechanisms in addition to the Kanagawa hemolysin.

Title

Effective ileal loop dose of Kanagawa-positive Vibrio parahaemolyticus.

Author

R M Twedt, J T Peeler, and P L Spaulding

Publish date

1980 Dec;

PMID

27980824

Abstract

The crystal and mol­ecular strutures of two solvated forms of [K(18c6)]OAc (18c6 = 18-crown-6 = 1,4,7,10,13,16-hexa­oxa­cyclo­octa­decane and OAc = acetate) were determined by single-crystal X-ray diffraction, namely (acetato-κ2 O,O′)(1,4,7,10,13,16-hexa­oxa­cyclo­octa­decane-κ6 O)potassium dihydrate, [K(CH3COO)(C12H24O6)]·2H2O (1) and (acetato-κ2 O,O′)aqua­(1,4,7,10,13,16-hexa­oxa­cyclo­octa­decane-κ6 O)potassium acetic acid monosolvate [K(CH3COO)(C12H24O6)(H2O)]·CH3COOH (2). In both compounds, the acetate anion is bonded to the potassium ion in a chelating fashion and the metal atom is consequently slightly displaced from the O6 plane of the crown ether. In the crystals, O—H⋯O hydrogen bonds lead to a polymeric ladder structure in the dihydrate 1, while the acetic acid hydrate 2 features inversion dimers.

KEYWORDS

crystal structure, potassium, crown ether, 18-crown-6, acetate, hydrate, hydro­acetate, hydrogen bridge bonds

Title

Crystal structures of two solvates of (18-crown-6)potassium acetate

Author

Phil Liebing,a Ahmad Zaeni,b Falk Olbrich,c and Frank T. Edelmanna,*

Publish date

2016 Dec 1;

PMID

31815961

Abstract

Murine leukemia virus (MLV) integrase (IN) lacking the C-terminal tail peptide (TP) loses its interaction with the host bromodomain and extraterminal (BET) proteins and displays decreased integration at promoter/enhancers and transcriptional start sites/CpG islands. MLV lacking the IN TP via an altered open reading frame was used to infect tumorigenesis mouse model (MYC/Runx2) animals to observe integration patterns and phenotypic effects, but viral passage resulted in the restoration of the IN TP through small deletions. Mice subsequently infected with an MLV IN lacking the TP coding sequence (TP-) showed an improved median survival by 15 days compared to wild type (WT) MLV infection. Recombination with polytropic endogenous retrovirus (ERV), Pmv20, was identified in seven mice displaying both fast and slow tumorigenesis, highlighting the strong selection within the mouse to maintain the full-length IN protein. Mapping the genomic locations of MLV in tumors from an infected mouse with no observed recombination with ERVs, TP-16, showed fewer integrations at TSS and CpG islands, compared to integrations observed in WT tumors. However, this mouse succumbed to the tumor in relatively rapid fashion (34 days). Analysis of the top copy number integrants in the TP-16 tumor revealed their proximity to known MLV common insertion site genes while maintaining the MLV IN TP- genotype. Furthermore, integration mapping in K562 cells revealed an insertion preference of MLV IN TP- within chromatin profile states associated with weakly transcribed heterochromatin with fewer integrations at histone marks associated with BET proteins (H3K4me1/2/3, and H3K27Ac). While MLV IN TP- showed a decreased overall rate of tumorigenesis compared to WT virus in the MYC/Runx2 model, MLV integration still occurred at regions associated with oncogenic driver genes independently from the influence of BET proteins, either stochastically or through trans-complementation by functional endogenous Gag-Pol protein.

Title

Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model

Author

Lorenz Loyola, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Visualization, Writing - original draft, Writing - review & editing,1 Vasudevan Achuthan, Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Software, Validation, Visualization, Writing - review & editing,2,3 Kathryn Gilroy, Data curation, Formal analysis, Writing - review & editing,4 Gillian Borland, Investigation,5 Anna Kilbey, Investigation,5 Nancy Mackay, Investigation,5 Margaret Bell, Investigation,6 Jodie Hay, Investigation,5 Sriram Aiyer, Formal analysis, Methodology,1 Dylan Fingerman, Investigation,1 Rodrigo A. Villanueva, Investigation,1 Ewan Cameron, Data curation, Funding acquisition, Resources, Supervision,6 Christine A. Kozak, Formal analysis, Visualization, Writing - review & editing,7 Alan N. Engelman, Funding acquisition, Project administration, Resources, Supervision, Writing - review & editing,2,3 James Neil, Conceptualization, Data curation, Formal analysis, Funding acquisition, Methodology, Project administration, Resources, Supervision, Validation, Visualization,5 and Monica J. Roth, Conceptualization, Funding acquisition, Investigation, Methodology, Project administration, Resources, Supervision, Validation, Visualization, Writing - original draft, Writing - review & editing1,* Bryan R. Cullen, Editor

Publish date

2019 Dec;